Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study

AIMS: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease. With this fixed dosing regimen, only approximately 40% of patients reach adequate plasma levels within the therapeutic index....

Descripción completa

Detalles Bibliográficos
Autores principales: Zuidema, Sander, Desar, Ingrid M.E., van Erp, Nielka P., Kievit, Wietske
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710511/
https://www.ncbi.nlm.nih.gov/pubmed/31112617
http://dx.doi.org/10.1111/bcp.13990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710511/
https://www.ncbi.nlm.nih.gov/pubmed/31112617
http://dx.doi.org/10.1111/bcp.13990

Ejemplares similares